Current Report Filing (8-k)
May 09 2017 - 4:17PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
May 3, 2017
AMARANTUS BIOSCIENCE HOLDINGS, INC.
(Exact name of registrant as specified
in its charter)
Nevada
|
|
000-55016
|
|
26-0690857
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File Number)
|
|
IRS Employer
Identification No.)
|
315 Montgomery Street, Suite 900
San Francisco, CA
|
|
94104
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(408) 737-2734
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant
to Rule 425 under the Securities Act
☐ Soliciting material pursuant
to Rule 14a-12 under the Exchange Act
☐ Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities
Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this
chapter). Emerging growth company
o
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act.
o
Item 5.02 Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 3 2017, Messrs.
Robert H. Trapp and Ronald Wei resigned as members of the Board of Directors of Amarantus BioScience Holdings, Inc. (the “Company”).
The resignations were not caused by any disagreement with the Company on any matter relating to the Company’s operations,
policies or practices. Mr. Wei will continue to serve as the Company’s Chief Financial Officer.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
AMARANTUS BIOSCIENCE HOLDINGS, INC.
|
|
|
|
Date: May 9, 2017
|
By:
|
/s/ Gerald E. Commissiong
|
|
Name:
|
Gerald E. Commissiong
|
|
Title:
|
Chief Executive Officer
|
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Amarantus Bioscience (CE) (USOTC:AMBS)
Historical Stock Chart
From Sep 2023 to Sep 2024